NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019.

Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company. We have benefitted from Dr. Goodman’s service on our Scientific Advisory Board since 2010. We look forward to the insights Dr. Goodman will bring to the Board.”

“It’s a pleasure to join a company with such a strong sense of purpose and a dedicated and experienced management team,” said Dr. Goodman. “I hope to offer a unique perspective to Tonix’s board and management team.”

Dr. Goodman served as a member of Tonix’s Scientific Advisory Board from 2010 until his appointment to the Board. Dr. Goodman is Chief Executive Officer and Founder of Riverside Pharmaceuticals, LLC which focuses on drug repurposing for treatments of neuropsychiatric diseases. He serves on the Board of Directors of PsychoGenics, Inc., a leading neuroscience drug discovery company with a proprietary, high throughput, informatics-driven platform for evaluating compounds for CNS disorders which it has partnered with several major pharmaceutical companies. PsychoGenics and its pharmaceutical partners have advanced multiple drugs into clinical trials which were either discovered or repurposed using its proprietary platforms. Dr. Goodman served as cofounder and CEO of PsychoGenics 1998-2000. Dr. Goodman practices psychiatry in New York City and Greenwich, CT at a practice that he founded in 2003 and which specializes in psychopharmacology, and is also President and cofounder of The Midtown Practice for Psychiatry, a group psychopharmacology and psychotherapy practice. Dr. Goodman is a Board-Certified psychiatrist and has served as a clinical assistant professor of psychiatry at Weill Cornell Medical College since 2006. Dr. Goodman was also cofounder and President of Resolvyx Pharmaceuticals which developed potential treatments for inflammation. Dr. Goodman earned an MBA from Columbia University, a medical degree from Harvard Medical School and a Diploma in Mathematic Statistics from Cambridge University, which he attended as a Churchill Fellow, after graduating from Yale College Summa Cum Laude in Mathematics.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya* (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for fibromyalgia and agitation in Alzheimer’s disease under separate INDs to support potential pivotal efficacy studies. The fibromyalgia program is in Phase 3 development and the agitation in Alzheimer’s program is Phase 2 ready. The agitation in Alzheimer’s disease IND has been designated a Fast Track development program by the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a different mechanism from TNX-102 SL and designed for daytime dosing. TNX-601 is also in development for a potential indication - neurocognitive dysfunction associated with corticosteroid use. A Phase 1 clinical formulation selection pharmacokinetic study of TNX-601 will be conducted outside of the U.S. in 2019. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.